Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients

Journal of the Royal Society Interface

Volumn 2, Issue 4, 2005, Pages 349-363

  Ferguson, N M ^a   Donnelly, C A ^a   Hooper, J ^a   Ghani, A C ^a   Fraser, C ^a   Bartley, L M ^a   Rode, R A ^b   Vernazza, P ^c   Lapins, D ^d   Mayer, S L ^e   Anderson, R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d Clinical Partners Inc   (United States)

^e Pascal Group Inc   (United States)

Author keywords

Adherence; Antiretroviral therapy; Compliance; HIV; Mathematical model; Protease inhibitor

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

EID: 33747105267     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2005.0037     Document Type: Article

References (49)

1. Abbott 1999 Norvir (ritonavir capsules) soft gelatin (ritonavir oral solution). Abbott Park, IL: Abbott Laboratories.
2. Abbott 2001 Kaletra (lopinavir/ritonavir) prescribing information Abbott Park, IL: Abbott Laboratories.
3. Adkins, J. C. & Faulds, D. 1998 Amprenavir. Drugs 55, 837-842.
4. Alexander, C. S., Asselin, J. J., Ting, L. S., Montaner, J. S., Hogg, R. S., Yip, B., O'Shaughnessy, M. V. & Harrigan, P. R. 2003 Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J. Infect. Dis. 188, 541-548.
5. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., Bamberger, J. D., Chesney, M. A. & Moss, A. 2000 Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14, 357-366.
6. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R. & Moss, A. 2001 Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181-1183.
7. Barry, M., Gibbons, S., Back, D. & Mulcahy, F. 1997 Protease inhibitors in patients with HIV disease. Clin. Pharmacokinet. 32, 194-209.
8. Bonhoeffer, S., May, R. M., Shaw, G. M. & Nowak, M. A. 1997 Virus dynamics and drug therapy. Proc. Natl Acad. Sci. USA 94, 6971-6976.
9. Buss, N., Snell, P., Bock, J., Hsu, A. & Jorga, K. 2001 Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br. J. Clin. Pharmacol. 52, 255-264.
10. De Boer, R. J. & Perelson, A. S. 1998 Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 190, 201-214.
11. Deeks, S. G., Smith, M., Holodniy, M. & Kahn, J. O. 1997 HIV-1 protease inhibitors a review for clinicians. J. Am. Med. Assoc. 277, 145-153.
12. Eron, J. J. et al. 2004 Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. 189, 265-272.
13. Ferguson, N. M. 2002 Why do people fail therapy? Modelling adherence and residual replication. In Overcoming resistance (ed. J. Weber), pp. 12-17. London: Mediscript.
14. Ferguson, N. M. et al. 1999 Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 96, 15 167-15 172.
15. Ferguson, N. M., Fraser, C. & Anderson, R. M. 2001 Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency. Trends Pharmacol. Sci. 22, 97-100.
16. Fraser, C., Ferguson, N. M. & Anderson, R. M. 2001 Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc. Natl Acad. Sci. USA 98, 15 167-15 172.
17. Frost, S. D. W., Martinez-Picado, J., Ruiz, L., Clotet, B. & Brown, A. J. L. 2002 Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J. Virol. 76, 968-979.
18. Frottier, J., Meynard, J. L., Morand-Joubert, L. & Guiguet, M. 1998 Factors predictive of early virologic response after a first treatment with a protease inhibitor in the course of HIV infection. Bull. Acad. Natl Med. 182, 981-992. (discussion 992 995).
19. Girard, P., Blaschke, T. F., Kastrissios, H. & Sheiner, L. B. 1998 A Markov mixed effect regression model for drug compliance. Stat. Med. 17, 2313-2333.
20. GlaxoSmithKline 2002 Agenerase (amprenavir) capsules. Research Triangle Park, NC: GlaxoSmithKline.
21. Gross, R., Bilker, W. B., Friedman, H. M. & Strom, B. L. 2001 Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 15, 2109-2117.
22. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
23. Hooper, J. 2002 Adherence, resistance and clinical response during antiretroviral therapy. Department of Zoology. University of Oxford.
24. Hsu, A. et al. 1998 Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 42, 2784-2791.
25. Jarvis, B. & Faulds, D. 1998 Nelfinavir: a review of its therapeutic efficacy in HIV infection. Drugs 56, 147-167.
26. Kastrissios, H., Suarez, J. R., Katzenstein, D., Girard, P., Sheiner, L. B. & Blaschke, T. F. 1998 Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 12, 2295-2303.
27. Kempf, D. J. et al. 1997 Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41, 654-660.
28. Knobel, H., Guelar, A., Carmona, A., Espona, M., Gonzalez, A., Lopez-Colomes, J. L., Saballs, P., Gimeno, J. L. & Diez, A. 2001 Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDs 15, 193-199.
29. Kurowski, M., Kaeser, B., Sawyer, A., Popescu, M. & Mrozikiewicz, A. 2002 Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Theor. 72, 123-132.
30. Liang, K. Y. & Zeger, S. L. 1986 Longitudinal data-analysis using generalized linear-models. Biometrika 73, 13-22.
31. Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D. & Havlir, D. V. 1999 Viral dynamics of acute HIV-1 infection. J. Exp. Med. 190, 841-850.
32. Masquelier, B. et al. 2002 Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR study. J. Infect. Dis. 186, 1503-1507.
33. Matthews, G. V., Sabin, C. A., Mandalia, S., Lampe, F., Phillips, A. N., Nelson, M. R., Bower, M., Johnson, M. A. & Gazzard, B. 2002 Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 16, 53-61.
34. McNabb, J. J., Nicolau, D. P., Stoner, J. A. & Ross, J. 2003 Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS 17, 1763-1767.
35. Melbourne, K. M., Geletko, S. M., Brown, S. L., Willey-Lessne, C., Chase, S. & Fisher, A. 1999 Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Read. 9, 329-338.
36. Merck & Co., Inc. 1999 Crixivan (indinavir sulfate) capsules.
37. Miller, L. G. & Hays, R. D. 2000 Measuring adherence to antiretroviral medications in clinical trials. HIV Clin. Trials 1, 36-46.
38. Molla, A. et al. 1998 Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250, 255-262.
39. Montaner, J. S., Hogg, R., Raboud, J., Harrigan, R. & O'Shaughnessy, M. 1998 Antiretroviral treatment in 1998. Lancet 352, 1919-1922.
40. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. 1996 HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 271, 1582-1586.
41. Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M. & Ho, D. D. 1997 Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191.
42. Phillips, A. N., Youle, M., Johnson, M. & Loveday, C. 2001 Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 15, 2211-2220.
43. Roche 1997 Fortovase (saquinavir). (1997). Nutley, NJ: Roche Laboratories, Inc.
44. Staszewski, S., Miller, V., Sabin, C. A., Carlebach, A., Berger, A. M., Weidmann, E., Helm, E. B., Hill, A. & Phillips, A. N. 1999 Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 13, 367-373.
45. van Heeswijk, R. P. G., Veldkamp, A. I., Hoetelmans, R. M. W., Mulder, J. W., Schreij, G., Hsu, A., Lange, J. M. A., Beijnen, J. H. & Meenhorst, P. L. 1999 The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDSU, F95-F99.
46. Vanhove, G. F., Schapiro, J. M., Winters, M. A., Merigan, T. C. & Blaschke, T. F. 1996 Patient compliance and drug failure in protease inhibitor monotherapy. J. Am. Med. Assoc. 276, 1955-1956.
47. Wahl, L. M. & Nowak, M. A. 2000 Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. B 267, 835-843. (doi:10.1098/rspb.2000.1079.)
48. Wong, D., Modi, R. & Ramanathan, M. 2003 Assessment of Markov-dependent stochastic models for drug administration compliance. Clin. Pharmacokinet. 42, 193-204.
49. Zeger, S. L. & Liang, K. Y. 1986 Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42, 121-130.